Feasibility of Tumor Immunoradiotherapy Using Radioiodinated Antibodies to Tumor-Specific Cell Membrane Antigens with Emphasis on Leukemias and Early Metastases

McGaughey, C.A.

doi:10.1159/000224913

Cited by 13 publications

(2 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The first two of these are being tested therapeutically in animal lymphomas. Radioisotope-antibody is being investigated widely for tumor imaging by gamma radiation, and has many theoretical attractions for tumor therapy [34] : its extension to therapy with antiidiotype is a possible future development.…”

Section: Development Of Cytotoxic Antibody Derivativesmentioning

confidence: 99%

Treatment of lymphoid tumors with anti-idiotype antibodies

Stevenson

1983

Springer Semin Immunopathol

View full text Add to dashboard Cite

Section: Development Of Cytotoxic Antibody Derivativesmentioning

confidence: 99%

Treatment of lymphoid tumors with anti-idiotype antibodies

Stevenson

1983

Springer Semin Immunopathol

View full text Add to dashboard Cite

“…This does not occur with boron neutron capture therapy. In addition, McGaughey (47) showed that only about one in several hundred antigen sites per tumor cell need to be occupied by radioiodinated anti-tumor antibodies for effective therapy. As will be shown later, this is a much smaller fraction of antigen sites than must be occupied by boron-bearing antibodies for effective therapy.…”

Section: The Use O F Tumor Antigens In the Selective Concentration O mentioning

confidence: 99%

Boron Neutron Capture Therapy of Cerebral Gliomas

et al. 1975

Oncology

View full text Add to dashboard Cite

The use of the blood-brain barrier and of tumor-specific antibodies to concentrate boron selectively in gliomas for neutron capture therapy is considered experimentally and theoretically. The time-dependent concentration of two anionic boranes, B₁₂H₁₁SH^2––and B₁₂H₁₁ SOSB₁₂H₁₁^4––, in the blood, brain, and tumor of rats bearing a tumor of gliomatous origin is reported. The rate of clearance of each anionic borane from the blood is correlated with the fraction of non-protein bound anion in the plasma. The use of antibodies to carry therapeutically useful amounts of boron to tumor-specific or tumor-associated antigens on the tumor cell surface will require different numbers of boron atoms bound per antibody depending on several immunological and physical parameters. Calculations using published values of antibody-antigen association constants and of cell surface antigen densities predict that in order to obtain 10 μg ¹⁰B/g tumor from 10 to over 10,000 boron-10 atoms will have to be bound per tumor antigenic site.

show abstract

Prospects for monoclonal antibody therapy of leukemia and lymphoma

Badger

Bernstein

1986

Cancer

View full text Add to dashboard Cite

The development of monoclonal antibodies has led to renewed interest in the use of antibodies to treat malignant disease. Unfortunately, treatment with unmodified antibodies has been disappointing. Therapy with unmodified antibodies has been limited by the failure of host effector mechanisms to eliminate antibody-coated tumor cells and by the emergence of variant cells lacking the target antigen. The use of antibodies as carriers of radionuclides has the potential for overcoming both these limitations because the conjugates will be directly cytotoxic and a conjugate bound to a cell surface will deliver radiation to adjacent cells lacking the target antigen. Experimental and clinical therapy trials of radionuclide antibody conjugates have yielded promising results with both tumor-specific antibody and with antibodies against differentiation antigens. Bone marrow toxicity has been dose limiting. Bone marrow support will most likely be required for the treatment of leukemia and lymphoma due to the marrow involvement with malignant cells. In the case of solid tumors, bone marrow infusion may allow administration of curative doses of radionuclide conjugates. Although at an early stage in development, radiolabeled antibodies have the potential for contributing significantly to the therapy of malignant disease.

show abstract

Feasibility of Tumor Immunoradiotherapy Using Radioiodinated Antibodies to Tumor-Specific Cell Membrane Antigens with Emphasis on Leukemias and Early Metastases

Cited by 13 publications

References 12 publications

Treatment of lymphoid tumors with anti-idiotype antibodies

Treatment of lymphoid tumors with anti-idiotype antibodies

Boron Neutron Capture Therapy of Cerebral Gliomas

Prospects for monoclonal antibody therapy of leukemia and lymphoma

Contact Info

Product

Resources

About